Abstract
The clinical, parasitological, hematological, and serological evolution of visceral leishmaniasis in Brazilian patients was assessed during treatment with human recombinant interferon-γ (rIFN-γ; 0.1 mg/m2 i.m. days 1-14) followed by pentavalent antimony (Sbv; 10 mg/kg days 22–28). At day 30,6 patients had improved, 2 had slightly improved, and 1 patient had deteriorated. IFN-γ was well tolerated in the dose tested and may be very effective as an adjunct to conventional therapy with antimony.
Get full access to this article
View all access options for this article.